Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

被引：0
作者：
Gabe S. Sonke
Lowell L. Hart
Mario Campone
Frans Erdkamp
Wolfgang Janni
Sunil Verma
Cristian Villanueva
Erik Jakobsen
Emilio Alba
Erik Wist
Anne M. Favret
Thomas Bachelot
Roberto Hegg
Paul Wheatley-Price
Farida Souami
Santosh Sutradhar
Michelle Miller
Caroline Germa
Howard A. Burris
机构：
[1] Netherlands Cancer Institute/BOOG Study Center,Department of Medical Oncology
[2] Florida Cancer Specialists,Zuyderland Medical Center
[3] Sarah Cannon Research Institute,University Hospital of Besançon
[4] Institut de Cancérologie de l’Ouest – René Gauducheau Centre de Recherche en Cancérologie,Virginia Cancer Specialists PC
[5] Sittard-Geleen/Heerlen,Ottawa Hospital Research Institute
[6] Universitätsklinikum Ulm,undefined
[7] Tom Baker Cancer Centre,undefined
[8] Hospital Jean-Minjoz,undefined
[9] Lillebælt Hospital,undefined
[10] Hospital Universitario Virgen de la Victoria,undefined
[11] IBIMA,undefined
[12] Oslo University Hospital,undefined
[13] US Oncology,undefined
[14] Centre Léon Bérard,undefined
[15] Hospital Pérola Byington Centro de Referência da Saúde da Mulher,undefined
[16] University of Ottawa,undefined
[17] Novartis Pharma AG,undefined
[18] Novartis Pharmaceuticals Corporation,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 167卷
关键词：
Breast cancer; CDK inhibitor; Ribociclib; Endocrine therapy; Elderly; Hormone receptor-positive;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：659 / 669
页数：10
相关论文
共 84 条
  • [1] Howlader N(2014)US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status J Natl Cancer Inst 106 dju055-73
  • [2] Altekruse S(2015)Treating elderly patients with hormone receptor-positive advanced breast cancer Clin Med Insights Oncol 9 65-3103
  • [3] Li C(2016)Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline J Clin Oncol 34 3069-33
  • [4] Chen V(2016)3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3) Ann Oncol 28 16-259
  • [5] Clarke C(2017)3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3) Breast 31 244-1153
  • [6] Ries L(2011)Current targeted therapies in breast cancer: clinical applications in the elderly woman Oncologist 16 1144-762
  • [7] Riseberg D(2014)Comprehensive geriatric assessment in the older cancer patient: coming of age in clinical cancer care Clin Pract (Lond) 11 749-432
  • [8] Rugo H(2013)Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2 Clin Breast Cancer 13 421-33
  • [9] Rumble R(2013)Breast cancer in the elderly-should it be treated differently? Rep Pract Oncol Radiother 18 26-vii40
  • [10] Macrae E(2013)Polypharmacy and the management of the older cancer patient Ann Oncol 23 vii36-1748
123456789